These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18006328)

  • 41. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
    Caponigro F
    Anticancer Drugs; 2004 Apr; 15(4):311-20. PubMed ID: 15057134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advances in EGFR-directed therapy in head and neck cancer.
    Numico G; Silvestris N; Grazioso Russi E
    Front Biosci (Schol Ed); 2011 Jan; 3(2):454-66. PubMed ID: 21196389
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy.
    Tortora G; Gelardi T; Ciardiello F; Bianco R
    Int J Biol Markers; 2007; 22(1 Suppl 4):S47-52. PubMed ID: 17520581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.
    Kendall A; Lord R; Maisey N
    Recent Pat Anticancer Drug Discov; 2010 Jun; 5(2):142-51. PubMed ID: 19954416
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monoclonal antibodies in the treatment of advanced colorectal cancer.
    Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
    Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study.
    Hörndler C; Gallego R; García-Albeniz X; Alonso-Espinaco V; Alonso V; Escudero P; Jimeno M; Ortego J; Codony-Servat J; Fernández-Martos C; Calatrava A; Marín-Aguilera M; Muñoz J; Castellví-Bel S; Castells A; Rubini M; Gascón P; Maurel J
    Cancer Biol Ther; 2011 Jan; 11(2):177-83. PubMed ID: 21099348
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.
    Lee D
    Clin Colorectal Cancer; 2004 Sep; 4(3):159-62. PubMed ID: 15377399
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
    Meyerhardt JA; Heseltine D; Ogino S; Clark JW; Enzinger PC; Ryan DP; Earle CC; Zhu AX; Fuchs CS
    Clin Colorectal Cancer; 2006 May; 6(1):59-65. PubMed ID: 16796793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
    Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
    J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.
    Gonçalves A; Esteyries S; Taylor-Smedra B; Lagarde A; Ayadi M; Monges G; Bertucci F; Esterni B; Delpero JR; Turrini O; Lelong B; Viens P; Borg JP; Birnbaum D; Olschwang S; Viret F
    BMC Cancer; 2008 Jun; 8():169. PubMed ID: 18544172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-EGFR therapy in colorectal cancer: how to choose the right patient.
    Meriggi F; Di Biasi B; Abeni C; Zaniboni A
    Curr Drug Targets; 2009 Oct; 10(10):1033-40. PubMed ID: 19663767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
    Grünwald V; Hidalgo M
    J Natl Cancer Inst; 2003 Jun; 95(12):851-67. PubMed ID: 12813169
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.
    Chua YJ; Cunningham D
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S81-8. PubMed ID: 16336753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor resensitization to erlotinib following brief substitution of cetuximab.
    Epstein RJ; Leung TW
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1111-2. PubMed ID: 18283460
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Siena S
    Handb Exp Pharmacol; 2018; 249():145-159. PubMed ID: 28382467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.